U.S. Pharmaceutical CDMO for Formulations Market - Databook 2025 to 2034

The U.S. pharmaceutical CDMO for formulations market size surpassed USD 10.15 billion in 2024 and is predicted to reach around USD 21.92 billion by 2034, registering a CAGR of 8% from 2025 to 2034.

Highlights of the U.S. Pharmaceutical CDMO for Formulations Market

By dosage form, the oral solids segment dominated the U.S. pharmaceutical CDMO for formulations market in 2024.
By dosage form, the injectables segment is observed to grow at the fastest rate in the pharmaceutical CDMO for formulations market during the forecast period.
By therapeutic area, the oncology segment dominated the U.S. pharmaceutical CDMO for formulations market in 2024.
By therapeutic area, the infectious diseases segment is observed to grow at the fastest rate in the U.S. pharmaceutical CDMO for formulations market during the forecast period.
By end user, the pharmaceutical companies segment dominated the U.S. pharmaceutical CDMO for formulations market in 2024.
By end user, the biopharmaceutical companies' segment is observed to grow at the fastest rate in the U.S. pharmaceutical CDMO for formulations market during the forecast period.

Industry Valuation and Growth Rate Projection

Industry Worth	Details
Market Size in 2025	USD 10.93 Billion
Market Size by 2034	USD 21.92 Billion
Market Growth Rate from 2025 to 2034	CAGR of 8%

CDMOs support pharmaceutical firms at all stages of the procedure of making medicines: by offering services in the R&D stages, by providing support in manufacturing, and by offering formulating and finishing procedures. CDMOs have been growing in the last decade, with a progressively dynamic mergers and acquisitions (M&A) landscape boosted by consolidation.

Market Trends

The requirement for outsourcing services is increasing due to the demand for cost-effective drug advancement and producing compliant with regulatory standards.
The increasing demand for biosimilars and biologics is boosting growth in the CDMO market, as these therapies need specialized expertise and production capabilities.
Artificial intelligence is becoming progressively implemented into CDMO processes, accelerating research, streamlining operations, and facilitating data analysis.

Restraints

CDMOs must stick to strict global regulations presiding over drug development, quality control, and production practices, which can be expensive and time-consuming. Evolving regulatory requirements over different regions thus complicates the landscape.
Establishing or upgrading facilities, mainly biologics and sterile manufacturing, demand remarkable financial investment.
Shifting client expectations, thus faster turnaround times and personalized solutions, set pressure on CDMOs to accept and innovate.

Opportunities

CDMOs can grip their expertise in specialized areas such as biologics, sterile liquids, and advanced therapies.
CDMOs can assist pharmaceutical firms reduce manufacturing expenses and streamline production.
Providing implemented services via the drug advancement and manufacturing process provides a competitive advantage.
CDMOs assure adherence to regulatory standards, guranteeing drug development and manufacturing.

Recent Developments in the U.S. Pharmaceutical CDMO for Formulations Market

In September 2024, PCI Pharma Services is perfusing more than $365 million in infrastructure understanding the clinical and commercial-scale final assembly and packaging of drug-device combination goods using advanced drug delivery systems, with a focus on injectable formats

Published by Deepa Pandey

U.S. Pharmaceutical CDMO for Formulations Market Segmentation:

By Dosage Form

Oral Solids
Oral Liquids
Injectables
Topicals
Inhalation Products
Transdermal And Patches
Others

By Therapeutic Area

Oncology
Cardiology
Central Nervous System
Gastroenterology
Infectious Diseases
Endocrinology (Diabetes, Hormonal Therapy)

By End User

Pharmaceutical Companies
Biopharmaceutical Companies
Others

U.S. Pharmaceutical CDMO for Formulations Market Companies:

Lonza
Catalent, Inc.
Thermo Fisher Scientific (Patheon)
Cambrex Corporation
Veranova
Fujifilm Diosynth Biotechnologies
WuXi Biologics
PCI Pharma Services
Adare Pharma Solutions
CordenPharma

Download PDF Help Center

Frequently Asked Questions

The market is valued at over US$ 10.93 billion and is expected to grow steadily.

U.S. pharmaceutical firms use CDMOs for formulations to grip expertise, speed up time-to-market, and reduce expenses associated with drug advancement and manufacturing.

In the U.S., the pharmaceutical CDMO domain is experiencing expansion, with major key players such as CordenPharma GmbH and Cambrex Corporation being major players. CDMOs are vital for pharmaceutical firms, offering drug development, API manufacturing, and formulation services.

Insightful Research, Impactful Results

Product Visualization
Bespoke Research Services
Experience Product Quality

Download

Stats ID:	8387
Format:	Databook
Published:	June 2025
Delivery:	Immediate

Proceed to Buy

	Data Book:	$ 1150
	Deep Dive Analysis:	$ 1550

CUSTOMIZE THIS REPORT

The report offers key market data-from trends to estimates and forecasts-customizable for strategic planning.

U.S. Market Statistics

Last Updated: 09 Jun 2025

Source: Statifacts

Last Updated: 09 Jun 2025

Source: Statifacts

U.S. Pharmaceutical CDMO for Formulations Market Revenue, By Dosage Form, 2024 to 2034 (USD Million)

Subsegment	2024	2025	2026	2027	2028	2029	2030	2031	2032	2033	2034
Oral Solids	4,576.14	4,928.48	5,312.73	5,732.10	6,190.16	6,690.82	7,238.50	7,838.05	8,494.90	9,215.07	9,896.86
Oral Liquids	1,699.89	1,828.52	1,968.65	2,121.42	2,288.10	2,470.10	2,668.97	2,886.44	3,124.43	3,385.08	3,630.99
Injectables	2,722.58	2,945.86	3,190.28	3,458.00	3,751.51	4,073.50	4,427.02	4,815.46	5,242.59	5,712.63	6,162.77
Topicals	1,110.20	1,190.93	1,278.66	1,374.07	1,477.90	1,590.98	1,714.23	1,848.65	1,995.37	2,155.63	2,305.57
Inhalation Products	622.45	671.20	724.41	782.54	846.10	915.64	991.79	1,075.23	1,166.75	1,267.19	1,362.59
Transdermal And Patches	400.65	430.77	463.57	499.31	538.30	580.85	627.33	678.13	733.71	794.55	851.87
Others	303.62	322.05	341.82	363.04	385.83	410.32	436.63	464.91	495.33	528.06	557.17

Last Updated: 09 Jun 2025

Source: Statifacts

References

Primary Research Interviews:

Key industry executives at pharmaceutical companies, CDMOs, and formulation companies.
Regulatory agencies like the FDA, which provide insights into compliance and regulations.
Market analysts and experts in the pharmaceutical outsourcing sector.
Contract managers in pharmaceutical companies and CDMOs.

Stakeholders:

Pharmaceutical companies (e.g., Big Pharma, generic drug manufacturers)
CMDOs (Contract Manufacturing and Development Organizations)
API manufacturers (Active Pharmaceutical Ingredients)
Regulatory bodies (FDA, EMA)
Research & Development teams in pharmaceutical companies
Logistics and packaging suppliers involved in pharmaceutical manufacturing

Databases:

IQVIA (pharmaceutical data, market analytics)
Evaluate Pharma (financials and forecasts for pharmaceutical companies)
Frost & Sullivan (market research reports, including CDMO market insights)

Magazines:

Pharmaceutical Technology (industry trends, CDMO focus)
Contract Pharma (specializes in contract manufacturing and development)
Drug Development & Delivery (focuses on drug development, CDMO services)
Pharma Manufacturing (covers pharmaceutical manufacturing, including CDMOs)
The Pharmaceutical Journal (research and analysis in the pharmaceutical sector)

Journals:

Journal of Pharmaceutical Sciences (research and development in pharmaceuticals)
Pharmaceutical Development and Technology (covers pharmaceutical development and contract services)
International Journal of Pharmaceutics (drug formulation, development, and manufacturing studies)
European Journal of Pharmaceutics and Biopharmaceutics (pharmaceutical formulation and development)

Newspapers:

The Wall Street Journal (business and economic news, including pharmaceutical outsourcing)
New York Times (business section for updates on the pharmaceutical industry)
Los Angeles Times (reports on the pharma industry, especially if based in California)

Associations:

Pharmaceutical Research and Manufacturers of America (PhRMA) (industry representation and updates)
International Society for Pharmaceutical Engineering (ISPE) (resources on pharmaceutical manufacturing and outsourcing)
Generic Pharmaceutical Association (GPhA) (advocates for generic drug manufacturers and CDMOs)
National Institute for Pharmaceutical Technology and Education (NIPTE) (research and education in pharmaceutical technology)

Public Domain Sources:

FDA.gov (regulations, approvals, and industry guidelines)
U.S. Census Bureau (for demographic and economic data related to pharmaceutical manufacturing)
U.S. Bureau of Labor Statistics (data on pharmaceutical manufacturing workforce)
World Health Organization (WHO) (international pharmaceutical guidelines and practices)

Proprietary Elements:

Custom surveys and market research from market research firms (e.g., Gartner, McKinsey)
CDMO client lists (from reports or direct outreach to companies)
In-house data from pharmaceutical companies (internal sales, product data, supply chain analysis)
Pharmaceutical industry-specific reports created by consulting firms or market analysts (Frost & Sullivan, BCC Research)

Insightful Research, Impactful Results

Product Visualization
Bespoke Research Services
Experience Product Quality

Download

Stats ID:	8387
Format:	Databook
Published:	June 2025
Delivery:	Immediate

Proceed to Buy

	Data Book:	$ 1150
	Deep Dive Analysis:	$ 1550

Related Reports

U.S. Pharmaceutical CDMO for Formulations Market - Databook 2025 to 2034

Highlights of the U.S. Pharmaceutical CDMO for Formulations Market

Industry Valuation and Growth Rate Projection